{"id":17785,"date":"2026-05-18T05:33:31","date_gmt":"2026-05-18T08:33:31","guid":{"rendered":"https:\/\/rtmedical.com.br\/tmp-en-1779093211064\/"},"modified":"2026-05-18T05:33:56","modified_gmt":"2026-05-18T08:33:56","slug":"cochrane-prostate-screening-mri-2026","status":"publish","type":"post","link":"https:\/\/rtmedical.com.br\/en\/cochrane-prostate-screening-mri-2026\/","title":{"rendered":"Cochrane Pivots to Support Prostate Cancer Screening"},"content":{"rendered":"

The Cochrane group, historically skeptical of population-based prostate cancer screening, reversed its stance in May 2026. A new systematic review concludes that PSA testing, combined with multiparametric magnetic resonance imaging as an intermediate filter, reduces prostate cancer mortality without the prohibitive overdiagnosis cost that had blocked the recommendation until now.<\/p>\n

\"Multiparametric
Multiparametric MRI, now embedded in the screening pathway, cuts unnecessary biopsies and refines the indication for treatment.<\/figcaption><\/figure>\n

What Changed In The Cochrane Position<\/h2>\n

Back in 2013, Cochrane published a position stating there was insufficient evidence that screening reduced prostate cancer mortality. Twelve years later, with longer follow-up from the large European and North American trials, the reading has flipped. The current review analyzed six clinical trials involving roughly 800,000 men and shows that PSA detects 30% more prostate cancers \u2014 most at an early stage \u2014 and reduces the relative risk of metastatic-stage diagnosis by 35%.<\/p>\n

The absolute mortality gain remains modest, around two deaths prevented per thousand men screened, compared with six to eight for mammography. But it is a real gain, and what underpins the change is the rise of magnetic resonance imaging as an intermediate filter: multiparametric MRI separates aggressive from indolent lesions before biopsy, attacking the Achilles’ heel of overdiagnosis.<\/p>\n

Why MRI Changed The Game<\/h2>\n

Prostate cancer is heterogeneous. Many lesions grow slowly, and many men live decades with the disease without it determining their outcome. Treating every elevated PSA with blind transrectal biopsy meant exposing patients to infections, bleeding, and discovery of irrelevant tumors, with avoidable surgeries and radiotherapies plus side effects like erectile dysfunction and urinary incontinence.<\/p>\n

Multiparametric MRI \u2014 combining T2, diffusion-weighted (DWI) and dynamic contrast-enhanced (DCE) sequences \u2014 assigns a PI-RADS score that stratifies risk before biopsy. PI-RADS 4 and 5 become targets for image-guided fusion biopsy; PI-RADS 1 and 2 can enter active surveillance. For broader clinical context, our coverage of how MRI models already predict molecular markers in breast cancer<\/a> shows the direction prostate imaging is also taking.<\/p>\n

The Numbers Behind The New Review<\/h2>\n

The Cochrane analysis consolidated data from trials like the European ERSPC, the U.S. PLCO and the British CAP, among others, with follow-up exceeding two decades in some arms. The key findings: 30% higher detection of prostate cancers overall, a 35% reduction in the relative risk of metastatic disease, and a gain of two deaths prevented per thousand men screened. On the other side, for every one to two deaths prevented, 36 additional cancers were diagnosed \u2014 a clear marker that overdiagnosis remains, but at a manageable magnitude when MRI triage sits between PSA and biopsy.<\/p>\n

The Cochrane authors also explicitly cited the success of MRI in reducing unnecessary biopsies. That is the central factor that turned a previously negative cost-benefit calculation into a cautious yet favorable recommendation. Reaching active surveillance at scale also depends on consistent workflows in well-integrated PACS environments<\/a> capable of comparing serial exams across years.<\/p>\n

Implications For Clinical Practice<\/h2>\n

Population-based prostate screening has never been consensus in Brazil. The Ministry of Health, INCA and SUS hold a conservative position, historically aligned with the U.S. Preventive Services Task Force before its most recent rethinking. Urology societies have long defended PSA starting at age 50 (45 for risk groups), while radiology has worked to consolidate multiparametric MRI as a mandatory exam before biopsy.<\/p>\n

The new Cochrane position strengthens the case for an organized screening model: baseline PSA, multiparametric MRI for elevated PSA, and fusion biopsy reserved for PI-RADS 4 and 5. That flow, common in European centers, is technically viable in Brazil \u2014 provided imaging clinics have 3 T machines (or 1.5 T with endorectal coil), radiologists with minimum reading volume, and standardized report templates.<\/p>\n

Limitations And Risks To Consider<\/h2>\n

The Cochrane review is not a blank check. Overdiagnosis is still real, even if reduced. Unequal access to MRI in the public health system can create two parallel pathways: properly filtered screening for those who can pay, direct biopsy for those relying on the public network. There is also the question of who reads the exams: screening programs only work where there is volume and expertise in genitourinary radiology \u2014 a national bottleneck.<\/p>\n

Monitoring mortality curves takes decades, and the real effect only becomes visible with mature follow-up. That means public health decisions need patience: regional pilot programs with long-term evaluation are wiser than a precipitous national rollout.<\/p>\n

What To Expect Next<\/h2>\n

The Cochrane pivot will likely pressure the USPSTF to revisit its recommendations, and similar moves should reach Europe within the next two years. In Brazil, the most predictable path goes through: updates to SBU and CBR guidelines, expanded ANS coverage for multiparametric prostate MRI in men with elevated PSA, and stronger active surveillance programs at reference centers.<\/p>\n

For radiologists in the trenches, the practical message is direct: build competence in prostate MRI, standardize PI-RADS protocols, strengthen the workflow with urologists and invest in second opinion. Prostate screening, once a pariah, is repositioning itself as one of the busiest fronts in oncologic radiology in 2026 and beyond.<\/p>\n

Source:<\/strong> The Imaging Wire \u2014 “Cochrane Pivots on Prostate Screening”<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Cochrane reverses its stance and supports PSA screening with multiparametric MRI as filter. See what changes in clinical practice.<\/p>\n","protected":false},"author":1,"featured_media":17781,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[100,99],"tags":[],"class_list":{"0":"post-17785","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-radiology","8":"category-radiotherapy"},"aioseo_notices":[],"rt_seo":{"title":"","description":"Cochrane reverses stance and supports PSA + multiparametric MRI screening for prostate cancer. See the practical impact for radiology.","canonical":"","og_image":"","robots":"index,follow","schema_type":"Article","include_in_llms":true,"llms_label":"Cochrane supports prostate screening","llms_summary":"Once skeptical, Cochrane now supports PSA + multiparametric MRI screening, which reduces unnecessary biopsies and overdiagnosis.","faq_items":[],"video":[],"gtin":"","mpn":"","brand":"","aggregate_rating":[]},"_links":{"self":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/17785\/"}],"collection":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/"}],"about":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/types\/post\/"}],"author":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/users\/1\/"}],"replies":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/comments\/?post=17785"}],"version-history":[{"count":1,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/17785\/revisions\/"}],"predecessor-version":[{"id":17787,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/17785\/revisions\/17787\/"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/17781\/"}],"wp:attachment":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/?parent=17785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/categories\/?post=17785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/tags\/?post=17785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}